State Street’s Takeda Pharmaceutical TAK Stock Holding History

State Street’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-47,877	Closed	-$653K	–	4925
2021 Q4	$653K	Sell	47,877 -946	-2%	-$13.3K	﹤0.01%	3922
2021 Q3	$800K	Sell	48,823 -2,811	-5%	-$47.2K	﹤0.01%	3832
2021 Q2	$869K	Sell	51,634 -11,999	-19%	-$204K	﹤0.01%	3691
2021 Q1	$1.16M	Buy	63,633 +3,933	+7%	+$70.8K	﹤0.01%	3589
2020 Q4	$1.09M	Sell	59,700 -2,452	-4%	-$43K	﹤0.01%	3539
2020 Q3	$1.11M	Sell	62,152 -923	-1%	-$16.8K	﹤0.01%	3409
2020 Q2	$1.13M	Buy	63,075 +14,548	+30%	+$261K	﹤0.01%	3386
2020 Q1	$737K	Sell	48,527 -51,529	-52%	-$934K	﹤0.01%	3371
2019 Q4	$1.97M	Sell	100,056 -302	-0.3%	-$5.78K	﹤0.01%	3258
2019 Q3	$1.73M	Sell	100,358 -2,560	-2%	-$44.3K	﹤0.01%	3265
2019 Q2	$1.82M	Buy	102,918 +8,102	+9%	+$147K	﹤0.01%	3276
2019 Q1	$1.93M	Buy	94,816 +62,171	+190%	+$1.25M	﹤0.01%	3164
2018 Q4	$549K	Buy	+32,645	New	+$551K	﹤0.01%	3431

Other funds holding TAK

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street's TAK Position: Q1 2022 in Review

State Street sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 47,877 shares — an estimated $653K sold.

State Street first reported a position in TAK in Q4 2018 and held it in 13 quarters. The position peaked at $1.97M in Q4 2019. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

State Street reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
State Street sold 47,877 Takeda Pharmaceutical shares in Q1 2022, an estimated $653K.
State Street first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 13 quarters.
State Street's Takeda Pharmaceutical position peaked at $1.97M in Q4 2019.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on State Street's 13F filing for Q1 2022, filed 16 May 2022.